Aimovig (Erenumab-aooe) for Migraine

Overview
- Approval: Aimovig is approved by the FDA to prevent migraines in adults.
- Type: It is a biologic drug, specifically a genetically engineered antibody.
- Class: Aimovig is the first member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) Show Full Answer

Aimovig (Erenumab-aooe) for Migraine

Overview:
- Approval: Aimovig is approved by the FDA to prevent migraines in adults.
- Type: It is a biologic drug, specifically a genetically engineered antibody.
- Class: Aimovig is the first member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists.
- Mechanism: It works by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

Administration:
- Method: Aimovig is administered as a subcutaneous injection once a month.
- Formats: It comes in prefilled, single-dose formats as a syringe or an autoinjector.

Side Effects:
- Common Side Effects: Constipation and injection site reactions.
- Long-term Effects: The long-term effects are not yet known due to the drug's newness.

User Experiences:
- Positive Feedback: Many users report positive results. For example:
- One user noticed a significant improvement after two weeks, with migraines reduced by 50%.
- Another user reported going 30 days without a migraine after five months of use.

For more details, you can visit the Aimovig website: [Aimovig.com – Amgen](https://www.aimovig.com/).

 This AI-generated response comes from MyMigraineTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Aimovig (Erenumab-aooe) for Migraine | MyMigraineTeam

Anti-CGRP Medications for Migraine | MyMigraineTeam